Cerivastatin-induced rhabdomyolysis: 11 case reports (Q34592173)

3 August 2017

1 reference

title

Cerivastatin-induced rhabdomyolysis: 11 case reports (English)

1 reference

3 August 2017

1 reference

Susan L Ravnan

1

1 reference

3 August 2017

Christy Locke

series ordinal

2

1 reference

3 August 2017

William P Yee

series ordinal

3

1 reference

3 August 2017

Kelli Haase

series ordinal

4

1 reference

3 August 2017

language of work or name

English

0 references

publication date

1 April 2002

1 reference

3 August 2017

1 reference

3 August 2017

22

1 reference

3 August 2017

4

1 reference

3 August 2017

533-537

1 reference

The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events Trial investigators

3 August 2017

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.22.7.533.33674

Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. West of Scotland Coronary Prevention Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.22.7.533.33674

Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, And Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III)

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.22.7.533.33674

HMG-CoA reductase inhibitors and myotoxicity

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.22.7.533.33674

Myopathy and rhabdomyolysis associated with lovastatin-gemfibrozil combination therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.22.7.533.33674

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.22.7.533.33674

Rhabdomyolysis and acute renal failure after changing statin-fibrate combinations

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.22.7.533.33674

Rhabdomyolysis and renal failure associated with cerivastatin-gemfibrozil combination therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.22.7.533.33674

Acute rhabdomyolysis associated with cerivastatin therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.22.7.533.33674

Helsinki Heart Study: primary-prevention trial with gemfibrozil in middle-aged men with dyslipidemia. Safety of treatment, changes in risk factors, and incidence of coronary heart disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.22.7.533.33674

Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high-density lipoprotein cholesterol. Veterans Affairs High-Density Lipoprotein Cholesterol Intervention Trial Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.22.7.533.33674

A method for estimating the probability of adverse drug reactions

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.22.7.533.33674

Combination therapy with cerivastatin and gemfibrozil causing rhabdomyolysis: is the interaction predictable?

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.22.7.533.33674

Rhabdomyolysis and acute renal failure induced by combination lovastatin and gemfibrozil therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.22.7.533.33674

Rhabdomyolysis due to simvastatin in a transplant patient: Are some statins safer than others?

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.22.7.533.33674

Rhabdomyolysis secondary to a drug interaction between simvastatin and clarithromycin

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.22.7.533.33674

Rhabdomyolysis and HMG-CoA reductase inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.22.7.533.33674

Pharmacological effects of HMG CoA reductase inhibitors other than lipoprotein modulation

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.22.7.533.33674

New insights into the pharmacodynamic and pharmacokinetic properties of statins.

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.22.7.533.33674

10.1592/PHCO.22.7.533.33674

21 January 2018

Identifiers

DOI

1 reference

3 August 2017

1 reference